Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

This source reports that four weeks of dupilumab treatment led to notable improvement in skin lesions, including multiple erythematous patches and papules on the face, back, and limbs.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

In this retrospective cohort study, patients using leflunomide for primary autoimmune conditions showed a decreased risk of developing alopecia areata, while those using methotrexate, cyclosporine, and rituximab had an increased risk.

In this case report, an 8-year-old with severe alopecia areata and atopic dermatitis experienced significant hair regrowth and improved dermatitis symptoms after treatment with dupilumab followed by baricitinib, with no major side effects observed.

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

This study reports that topical fish oil treatment in GsdmA3 Dfl/+ mice increased cellular proliferation and macrophages but did not affect COX-2 expression related to psoriasis-like skin changes.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

This case report details a 47-year-old female with atopic dermatitis who developed alopecia areata after six months on dupilumab therapy; treatment discontinuation and other interventions led to complete hair regrowth, suggesting dupilumab may trigger alopecia areata in patients with atopic or autoimmune predispositions.

In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.

This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This study observed that DMAP scaffolds in a full-thickness wound model promote dermal appendage regeneration by activating humoral immunity, specifically through B cell activation and antibody production, even when adaptive immune cells' infiltration is restricted.

This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.

This study found that in a mouse model, betamethasone dipropionate reduced epidermal thickness while fish oil unexpectedly increased it, validating optical coherence tomography as an effective measurement tool.

This case study highlights that primary biliary cholangitis in a patient with systemic lupus erythematosus can respond well to ursodeoxycholic acid therapy, and anti-DFS70 findings may require further evaluation for other nonsystemic autoimmune conditions.

This case report observed that oral tofacitinib treatment resolved both alopecia universalis and plaque psoriasis in a patient, possibly by targeting shared inflammatory pathways.

This source explores the potential use of oral bicalutamide for treating female pattern hair loss, but specific results or outcomes from the study are not reported in the abstract.

This case report suggests that starting selective Janus kinase 1 inhibition may improve alopecia in a patient with rheumatoid arthritis who was not responding to TNF-α inhibitor therapy and corticosteroids.

This review describes the evolution of treatments for relapsing multiple sclerosis, highlighting that while newer potent monoclonal agents can potentially achieve disease remission, they also pose moderate to severe adverse event risks that healthcare providers must understand.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This study reported that specific inhibition of the classical complement pathway with BIVV009 prevented C3 deposition along the dermal-epidermal junction in bullous pemphigoid, reflecting its potential efficacy.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This case report describes a patient who developed multiple skin reactions, including eczematous lesions and alopecia areata, during adalimumab treatment, but found no improvement in pustulosis palmoplantaris with different biologics.